Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Immunol. 2012 Jul 23;189(5):2151–2158. doi: 10.4049/jimmunol.1103741

Figure 3.

Figure 3

Pharmacological inhibition of mTOR augments the duration of costimulatory molecule expression in human myeloid DCs. (A) Human myeloid DCs were either unstimulated or stimulated with R848 in the presence or absence of rapamycin (RAP) or KU. CD40 and CD86 expression was analyzed by FACS. Day 4 costimulatory molecule expression from a representatitve donor (5430) is depicted. (B) DCs were treated as in (A) and analyzed daily by FACS for CD40 and CD86 expression. (C) DCs were treated as in (A) and analyzed for viability at indicated times by FACS analysis of 7-AAD staining. For each treatment, data from 4–6 individual donors is depicted.